Transarterial chemoembolization for patients with hepatocellular carcinoma

Area of Science:

• Hepatology
• Medical Oncology
• Gastroenterology

Background:

• Hepatocellular carcinoma (HCC) incidence is rising globally, prompting research into improved diagnostics and treatments.
• Current screening methods diagnose only 30% of HCC cases at early, treatable stages.
• Radical treatments like resection and transplantation are only viable for early-stage HCC.

Purpose of the Study:

• To review the current diagnostic and therapeutic landscape for Hepatocellular Carcinoma (HCC).
• To evaluate the efficacy and limitations of existing HCC treatment modalities.
• To identify the need for further research in HCC management.

Main Methods:

• Review of current screening protocols for HCC in cirrhotic patients.
• Analysis of therapeutic options for advanced HCC, including transarterial chemoembolization (TACE).
• Assessment of eligibility criteria, response rates, and adverse effects associated with TACE.

Main Results:

• Only 30% of HCC cases are diagnosed early enough for radical treatment.
• Transarterial chemoembolization (TACE) is the only therapy showing survival benefits for advanced HCC.
• TACE is suitable for <20% of HCC patients due to strict criteria; objective response rates range 20-50% with significant adverse effects.

Conclusions:

• HCC diagnosis and treatment remain significant challenges, with limited options for many patients.
• Transarterial chemoembolization (TACE) has demonstrated survival benefits but is underutilized due to strict criteria and side effects.
• Further randomized controlled trials are essential to optimize chemotherapeutic agents and re-treatment schedules for HCC.